OPGN Opgen Inc

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2019

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2019

GAITHERSBURG, Md., March 12, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will report its fourth quarter and full year 2019 financial results after the close of the U.S. financial markets on Tuesday, March 24, 2020. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.

Conference Call Details
 U.S. Dial-in Number:(844) 420-8185
 International Dial-in Number:+1 (216) 562-0481
 Webcast:
 Conference ID:3497986
   
Reply Details
 U.S. Dial-in Number:(855) 859-2056
 International Dial-in Number: +1 (404) 537-3406
 Conference ID:3497986

Following the conclusion of the conference call, a replay will be available through March 31, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at . A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days.

About OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.

Our molecular diagnostics and informatics products, product candidates and services combine our Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with our proprietary, curated MDRO knowledgebase. We are working to deliver our products and services, some in development, to a global network of customers and partners. The Acuitas AMR Gene Panel (RUO) is intended for Research Use Only and is not for use in diagnostic procedures. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures. For more information, please visit .

OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc.

OpGen Contact:

Michael Farmer

Vice President, Marketing

(240) 813-1284

Press Contact:

Matthew Bretzius

FischTank Marketing and PR

Investor Contacts:

Joe Green

Edison Group

EN
12/03/2020

Underlying

OPGNOpgen Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Opgen Inc

 PRESS RELEASE
Free
OPGN OPGEN INC

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”), which serves as an additional basis for delisting the Company’s securities from Nasdaq, and that the Nasdaq Hearings Panel will consider...

May 24, 2024 1 EN
 PRESS RELEASE
Free
OPGN OPGEN INC

OpGen Announced 1-for-10 Reverse Stock Split

OpGen Announced 1-for-10 Reverse Stock Split ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company’s board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol “OPGN.” The new CUSIP number for the Company’s common stock fol...

May 16, 2024 1 EN
 PRESS RELEASE
Free
OPGN OPGEN INC

OpGen Provides Update on Business Operations and Strategic Opportuniti...

OpGen Provides Update on Business Operations and Strategic Opportunities ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000. The transaction follows Camtech’s prior acquisition of all of Curetis GmhH’s (“Curetis”), the Company’s subsidiary, Unyvero assets, rights and businesses, as part of Curetis’ insolvency proceedings. In addit...

April 29, 2024 1 EN
 PRESS RELEASE
Free
OPGN OPGEN INC

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic reports with the Securities and Exchange Commission (...

April 23, 2024 1 EN
 PRESS RELEASE
Free
OPGN OPGEN INC

OpGen Announces Acquisition of Preferred Stock by David Lazar

OpGen Announces Acquisition of Preferred Stock by David Lazar David Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred Stock (“Series E Preferred Stock”)...

March 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch